- Home
- PTLO vs ACIU Comparison
PTLO vs ACIU Comparison
Compare PTLO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTLO | ACIU |
|---|---|---|
| Founded | 1963 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.0M | 229.0M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PTLO | ACIU |
|---|---|---|
| Price | $4.46 | $2.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $8.06 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.7M | 290.6K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $732,066,000.00 | N/A |
| Revenue This Year | $9.02 | $706.75 |
| Revenue Next Year | $5.81 | $321.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $3.78 | $1.65 |
| 52 Week High | $12.29 | $4.00 |
Technical Indicators
Market Signals| Indicator | PTLO | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 31.71 |
| Support Level | $3.79 | $2.03 |
| Resistance Level | $6.09 | $3.92 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 92.75 | 12.83 |
Price Performance
Historical ComparisonAbout PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.